Werewolf Therapeutics Inc’s recently made public that its Shareholder MPM BioVentures 2014, L.P. acquired Company’s shares for reported $89370.0 on Dec 22 ’25. In the deal valued at $0.69 per share,130,125 shares were bought.
Then, MPM Asset Management Investors bought 4,479 shares, generating $3,076 in total proceeds.
Before that, UBS Oncology Impact Fund, L.P. bought 107,463 shares. Werewolf Therapeutics Inc shares valued at $73,806 were divested by the Shareholder at a price of $0.69 per share.
Wedbush downgraded its Werewolf Therapeutics Inc [HOWL] rating to a Neutral from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in early April with a ‘”a Mkt outperform”‘ rating. Wedbush began covering HOWL with “an Outperform” recommendation on August 24, 2023.
Price Performance Review of HOWL
On Monday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock fall -2.53% to $0.67. Over the last five days, the stock has lost -35.01%. Werewolf Therapeutics Inc shares have fallen nearly -54.77% since the year began. Nevertheless, the stocks have fallen -54.77% over the past one year. While a 52-week high of $2.38 was reached on 09/29/25, a 52-week low of $0.56 was recorded on 12/18/25.
Levels Of Support And Resistance For HOWL Stock
The 24-hour chart illustrates a support level at 0.6383, which if violated will result in even more drops to 0.6072. On the upside, there is a resistance level at 0.7202. A further resistance level may holdings at 0.7710.
How much short interest is there in Werewolf Therapeutics Inc?
A steep rise in short interest was recorded in Werewolf Therapeutics Inc stocks on 2025-11-28, growing by 0.12 million shares to a total of 1.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 0.9 million shares. There was a rise of 11.94%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 10, 2021 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $26 price target.
